tbuckley/cabot-search huggingface dataset:
Effect of fulvestrant treatment on serum VEGF levels in hormone-sensitive metastatic breast cancer patients
Authors: A. Camerini, O. Garrone, C. Valsuani, C. Puccetti, M. Rondini, S. Donati, O. Siclari, S. Barni, P. Pronzato, D. Amoroso
Journal: Journal of Clinical Oncology (2009)

1124 Background: Fulvestrant (F) is a pure antiestrogen agent available for the hormonal treatment (HT) of post-menopausal ormone-sensitive advanced breast cancer (ABC). We previously reported (ASCO 2007 abs1085) a lipid lowering effect of F possibly related to an action on progesterone (P) receptor. Aim of the study is to analyze the effect of F treatment on serum VEGF levels that may represent an effect of P pathway alteration. Methods: 21 pts (median age 75 yrs [range 43–82]) with hormone-sensitive ABC were enrolled. All patients were heavily pretreated receiving a median of 2 [1–4] HT-lines and 2 [1–5] CT-lines before F. Last HT before F administration was exemestane in 8/21, letrozole in 9/21, anastrozole 3/21, and tamoxifene in 1/21. Treatment-related data, including response according to RECIST criteria and toxicity, were collected. Fulvestrant was administered as standard monthly 250 mg injection. Peripheral venous blood samples were collected before F administration, every 3 months, and at discontinuation time. VEGF levels were evaluated by ELISA and expressed as absolute absorbance values. Baseline values were always compared to the last available sample. Results: At report time pts received a median of 4 F injections (range 3–8). We observed a PR in 3/21, SD in 7/21, and PD in 11/21 pts with a clinical benefit of 45% and a median TTP of 4.5 [3–9] months. Serum VEGF levels significantly decreased during F treatment (156.8 ± 28.5 vs. 122.2 ± 14.5 A; p = 0.01). VEGF reduction was independent from clinical benefit (186.4 ± 44.6 vs. 131.1 ± 21.8 A, p = 0.04 in pts with CB and 158.9 ± 52.5 vs. 125.0 ± 27.9 A, p = 0.1 ns in pts without CB), type of last HT or treatment duration. Conclusions: We observed a reduction of serum VEGF levels associated with F treatment in our study population. Our data seem to strengthen the hypothesis of a possible effect of F on P pathway affecting both lipid metabolism and VEGF production regulation. No significant financial relationships to disclose.
Hemolytic Anemia and Thromobocytopenia Associated with Ischemic Brain Lesions in Patients with Acute Uncomplicated Plasmodium Falciparum Malaria.
Authors: Gary M. Brittenham, Christina L.V. Tosti, Xavier Golay, Marc Van Cauteren, Varinee Lekprasert, Noppadon Tangpukdee, Srivicha Krudsood, Wattana Leowattana, Polrat Wilairatana, Srirama V. Swaminathan, Robert L. DeLaPaz, Truman R. Brown, Sornchai Looareesuwan, Jiraporn Laothamatas
Journal: Blood (2006)
Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses’ Health Study 2
Authors: A. M. Drucker, J. M. Thompson, W.‐Q. Li, E. Cho, T. Li, E. Guttman‐Yassky, A. A. Qureshi
Journal: Allergy (2017)

Abstract We aimed to determine the risk of alopecia areata ( AA ) and vitiligo associated with atopic dermatitis ( AD ) in a large cohort of US women, the Nurses’ Health Study 2. We used logistic regression to calculate age‐ and multivariate‐adjusted odds ratios to determine the risk of incident AA and vitiligo associated with AD diagnosed in or before 2009. A total of 87 406 and 87 447 participants were included in the AA and vitiligo analyses, respectively. A history of AD in 2009 was reported in 11% of participants. There were 147 incident cases of AA and 98 incident cases of vitiligo over 2 years of follow‐up. AD was associated with increased risk of developing AA ( OR 1.80, 95% CI 1.18–2.76) and vitiligo ( OR 2.14, 95% CI 1.29–3.54) in multivariate models. In this study of US women, AD was associated with increased risk of incident vitiligo and AA in adulthood.
Targeting FLT3 Phosphorylation and Signaling in Acute Myeloid Leukemia.
Authors: Alan K. Ikeda, Dejah Judelson, Junling Li, Ru Qi Wei, Paul Tapang, Steven K. Davidsen, Dan H. Albert, Keith B. Glaser, Cecilia Fu, Kathleen M. Sakamoto
Journal: Blood (2007)
Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications.
Authors: Constantine S. Mitsiades, Luba Benimetskaya, Krishna Menon, Cinara Echart, Cecile Rouleau, Beverly Teicher, Antonio Palumbo, Mario Boccadoro, Massimo Iacobelli, Kenneth C. Anderson, Cy A. Stein, Paul G. Richardson
Journal: Blood (2006)
Dose Adjustment and Use of Alternative Eltrombopag Dosing Regimens for the Treatment of Patients with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Authors: Athanasios Galanopoulos, Panagiotis Bacarakos, Dimitris Tsokanas, Ilias Minakakis, Zoi Topouzoglou, Georgia Leveta, Theodore Marinakis, Christina Papadaki, Vasiliki Grigoraki, Elpiniki Griva-Kritikou, Anagnostopoulos I. Nikolaos
Journal: Blood (2012)
Reevaluation of Factors Leading to the Successful Isolation of Mesenchymal Stem Cells From Human Umbilical Cord Blood and Their Differentiation to Mesenchymal Lineages.
Authors: Xiaohong Zhang, Masako Hirai, Susana Cantero, Rodica Ciubotariu, Allen Hirsh, Hitoshi Satoh, Izuru Yokomi, Kotaro Yoshimura, Toshihide Nishimura, Satoru Yamaguchi, Koichi Igura, Pablo Rubinstein, Tsuneo A. Takahashi, DSc
Journal: Blood (2009)
Relationship between JAK2 V617F Mutation Status, Granulocyte CD177 mRNA Expression and CD177 Soluble Protein Level in Patients with Polycythemia Vera.
Authors: Daniela Pietra, Alessandra Balduini, Carmela Marseglia, Matteo G. Della Porta, Luca Malcovati, Isabella Pallotta, Francesco Passamonti, Mario Cazzola
Journal: Blood (2005)
Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Authors: James M. Foran, Cristine Allmer, Alice H Wang, Carrie A. Thompson, Jennifer L. Kelly, Grzegorz S. Nowakowski, Matthew J Maurer, Susan L Slager, David J. Inwards, Stephen M. Ansell, Thomas E. Witzig, Brian K Link, Thomas M Habermann, James R Cerhan
Journal: Blood (2012)
Reasons for drug policy reform: prohibition enables systemic human rights abuses and undermines public health
Authors: Dainius Pūras, Julie Hannah
Journal: BMJ (2017)

Drug prohibition, including criminalisation to regulate the supply and demand of controlled substances, has had devastating effects on human rights and public health worldwide.Prohibition as an international policy response gives rise to illicit drug markets governed by criminal networks and regulated by violence.The poor and marginalised communities in which illicit drugs are cultivated, transited, or sold are disproportionately affected.States have responded with increased law enforcement, escalating violence and further destabilising communities.Parallel violent pursuits both to protect and to topple illicit markets have been linked to large scale displacement, femicide, and an overall decrease in life expectancy, such as in Mexico.
Engineering of Human T-Cells with a Novel Aurora-A Kinase-Specific T-Cell Receptor Gene Transfer Confers Anti-Leukemia Reactivity
Authors: Kozo Nagai, Hiroshi Fujiwara, Toshiki Ochi, Jun An, Toshiaki Shirakata, Junichi Mineno, Kiyotaka Kuzushima, Hiroshi Shiku, J. Joseph Melenhorst, Emma Gostic, David A Price, Masaki Yasukawa
Journal: Blood (2010)
Expression Levels of a Single Gene, Lymphoid Enhancer Binding Factor 1, Discriminates CLL B-Cells from Other B-Cell Malignancies.
Authors: Brian A. McCarthy, Mike Tipping, Xue Ping Wang, Fiona Bennet, Wentian Li, Martin Lesser, Santanu Paul, Erin Boyle, Carol Moreno, Rosa Catera, Bradley T. Messmer, Steven L. Allen, Andrew C. Rawstron, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2007)
Microparticle-Associated Thrombin Generation and Procoagulant Activity Is Increased In Patients with Essential Thrombocythemia
Authors: Annamaria Leuzzi, Marina Marchetti, Marina Panova-Noeva, Carmen Julia Tartari, Laura Russo, Alessandro Rambaldi, Guido Finazzi, Tiziano Barbui, Barry John Woodhams, Anna Falanga
Journal: Blood (2010)
Results of the Largest Study on Post-Transplant-Lymphoproliferations (PTLDs) of the Central Nervous System (CNS) in the Rituximab Era: A Surprising Overrepresentation of Kidney Transplantations, Key Importance of Methotrexate (Mtx), Cytarabine (AraC) and Radiotherapy (RX) for Long Term Survival and Low Impact of Rituximab (R)
Authors: Sylvain Choquet, Stefan Oertel, Ioannis Anagnostopoulos, Hanno Riess, Madalina Uzunov, V.éronique Leblond, Ralf Trappe
Journal: Blood (2008)
Second Allogeneic Stem Cell Transplantation (allo-SCT) Using Reduced-Intensity Conditioning (RIC) for Acute Myeloid Leukemia (AML) Patients Who Relapsed Following a First RIC Allo-SCT: a Survey From the Acute Leukemia Working Party of EBMT.
Authors: Mohamad Mohty, Myriam Labopin, Jurgen Finke, Christoph Schmid, H.J. Kolb, Andrea Bacigalupo, Didier Blaise, Jérôme Cornillon, Noel Milpied, J.R. Cabrera-Marin, Fabio Ciceri, Vanderson Rocha, Arnon Nagler
Journal: Blood (2010)
Use of denaturing high performance liquid chromatography (dHPLC) for detection of EGFR mutations in patients with NSCLC
Authors: J. S. Agulnik, V. Cohen, J. Jarry, G. Batist, D. Small, H. Kreisman, N. A. Tejada, G. Chong, W. H. Miller
Journal: Journal of Clinical Oncology (2006)

10068 Background: Somatic mutations of the epidermal growth factor receptor (EGFR) gene may predict responsiveness to tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC). These mutations are commonly identified using DNA sequencing methods. Although considered the gold standard, this approach is expensive and time-consuming. In addition, a high ratio of tumour to normal tissue DNA is required for optimal results which is not often available in biopsies obtained from these patients. The primary objective of this study was to develop a rapid and sensitive method for screening of EGFR mutations. Materials and Methods: Clinical specimens from 110 NSCLC patients were analysed for EGFR mutations in exons 19 and 21. After DNA extraction and PCR, both dHPLC and direct sequencing were performed and results were compared. Results: Sequencing revealed a total of 7 (6%) mutations: 4 missense mutations in exon 21 and 3 deletion mutations in exon 19. dHPLC showed the presence of genomic alterations in 18 (16%) samples, including the 7 identified by sequencing plus 11 additional samples (10 in exon 19 and one in exon 21). dHPLC fractions were isolated, reamplified, and sequenced to confirm these results. In serial dilution studies, dHPLC was able to detect mutations in samples containing as little as 10% mutated DNA whereas direct sequencing required at least 30%. Conclusions: dHPLC is an efficient and accurate, as well as a a more sensitive method for screening of genomic alterations in exons 19 and 21 of the EGFR gene compared to direct sequencing. This data suggests that dHPLC should be implemented as a screening tool for detection of EGFR mutations. No significant financial relationships to disclose.
Single Cell Analysis Proves the Coexistence of NOTCH1 and TP53 Mutations within the Same Cancer Cells in Patients with Chronic Lymphocytic Leukemia
Authors: Barbara Kantorova, Jitka Malcikova, Kamila Brazdilova, Marek Borsky, Karla Plevova, Jana Smardova, Martin Trbusek, Yvona Brychtova, Michael Doubek, Jiri Mayer, Sarka Pospisilova
Journal: Blood (2015)
Hypercoagulation Screening As a Marker of Thrombosis and Poor Disease Prognosis in Cancer Patients: The Hypercan Prospective Study
Authors: Marina R Marchetti, Giovanna Masci, Armando Santoro, Filippo de Braud, Luigi Celio, Roberto Labianca, Mario Mandalà, Barbara Merelli, Carlo Tondini, Giampietro Gasparini, Roberta Sarmiento, Carmen J Tartari, Cinzia Giaccherini, Francesca Piras, Cristina Verzeroli, Luca Barcella, Alfonso Vignoli, Anna Falanga
Journal: Blood (2014)
Bone Mineral Density, Fracture Risk and Avascular Bone Necrosis in Childhood Acute Lymphoblastic Leukemia; an Up-Date of the Prospective DUTCH ALL9 Study.
Authors: Marry M. Van den Heuvel-Eibrink, Inge M. Van der Sluis, Bert A. Leeuw, Gaby Kardos, Lizet M. te Winkel, Tom Revesz, Elisabeth T. Korthof, Jos Bokkerink, Anjo J.P. Veerman
Journal: Blood (2004)
Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.
Authors: Karoline V. Gleixner, Mayerhofer Matthias, Anja Vales, Alexander Gruze, Michael Kneidinger, Gregor Hoermann, Maria T. Krauth, Rudin Kondo, Karoline Sonneck, Puchit Samorapoompichit, Eva Lackner, Khaled Greish, Winfried F. Pickl, Christian Sillaber, Christoph C. Zielinski, Hiroshi Maeda, Peter Valent
Journal: Blood (2006)
Targeting Histone Deacetylases As a New Strategy for Graft Versus Host Disease Prevention
Authors: Sung W. Choi, John F. DiPersio, Thomas M. Braun, Guoqing Hou, Keith Stockerl-Goldstein, Isao Tawara, John E. Levine, Yaping Sun, Daniel R. Couriel, Oleg I. Krijanovski, Lawrence Chang, John M. Magenau, Attaphol Pawarode, Carrie Kitko, Sophie Paczesny, Edward M. Peres, Shin Mineishi, Gregory A. Yanik, Michael Lehmann, Charles A. Dinarello, James L.M. Ferrara, Pavan Reddy
Journal: Blood (2012)
Apoptosis Stimulating Protein of p53 (ASPP2) Haploinsufficiency Promotes Irradiation-Induced High Grade Lymphomas in a Mouse Model.
Authors: Kerstin M. Kampa, Jared D. Akoba, Dexi Chen, Kelly Beemer, Joel Gay, Zhiyi Zhu, Emerson Padiernos, Christopher Corless, Alexis Baily, William H. Flemming, Charles D. Lopez
Journal: Blood (2007)
Serum Thymidine Kinase Level in Chinese Chronic Lymphocytic Leukemia and Its Correlation with Other Prognostic Factors
Authors: Jianyong Li, Wei Xu, Hui Yu, Hongxia Qiu, Chun Qiao, Yu-Jie Wu, Qiong Liu, Danxia Zhu, Kourong Miao
Journal: Blood (2008)
Synaptic Plasticity onto Dopamine Neurons Shapes Fear Learning
Authors: Marco Pignatelli, George Kwabena Essien Umanah, Sissi Palma Ribeiro, Rong Chen, Senthilkumar Senthil Karuppagounder, Hau-Jie Yau, Stephen Eacker, Valina Lynn Dawson, Ted Murray Dawson, Antonello Bonci
Journal: Neuron (2017)
Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
Authors: Clemens Wendtner, Peter Hillmen, Daruka Mahadevan, Stephan Stilgenbauer, Lutz Uharek, Steven Coutre, Olga Frankfurt, Adrian Bloor, Francesc Bosch, Richard R. Furman, Eva Kimby, John G. Gribben, Marco Gobbi, Luke Dreisbach, David Duane Hurd, Mikkael A. Sekeres, Alessandra Ferrajoli, Sheetal Shah, Jennie Zhang, Laure Moutouh de Parseval, Asher A. Chanan-Khan
Journal: Blood (2010)
Early Immunoglobulin Free Light Chain (FLC) Response Post Autologous Peripheral Blood Stem Cell Transplant Predicts for Hematologic Complete Response in Patients with Multiple Myeloma.
Authors: Angela Dispenzieri, S. Vincent Rajkumar, Matthew F. Plevak, Jerry A. Katzmann, Robert A. Kyle, Dirk Larson, Martha Q. Lacy, Raynell Clark, Roberta DeGoey, Suzanne R. Hayman, Shaji K. Kumar, Morie Abraham Gertz
Journal: Blood (2006)
Correlation Between Clinical Responses and Immune Characteristics in Patients with Relapsed CLL Treated with Ofatumumab and Lenalidomide
Authors: Candida Vitale, Lorenzo Falchi, Elisa ten Hacken, Hui Gao, Hila Shaim, Katrien Van Roosbroeck, George Calin, Susan O'Brien, Stefan Faderl, Xuemei Wang, William Wierda, Katayoun Rezvani, James M Reuben, Jan A. Burger, Michael Keating, Alessandra Ferrajoli
Journal: Blood (2015)
Severity of Chronic Gvhd and Personality Determines Quality of Life and the Activity Profile: Results of a Prospective German Multicenter Validation Trial
Authors: Daniel Wolff, Philipp Herzberg, Pia Heussner, Friederike Mumm, Inken Hilgendorf, Stephanie von Harsdorf, Armin Gerbitz, Hildegard T. Greinix, Joachim Hahn, Christian Junghanss, Ernst Holler
Journal: Blood (2008)
Pre-Transplant Test Dose vs. PK Studies during Conditioning Regimen To Target iv Busulfan in Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Sandeep Chunduri, Rakesh Beri, Lisa C. Dobogai, Elizabeth Hurter, Christina Mactal-Haaf, Karen I. Sweiss, Stacy Shord, David Peace, Damiano Rondelli
Journal: Blood (2007)
The Expression of Platelet Membrane Glycoproteins in Patients with Myelodysplastic Syndrome (MDS).
Authors: Fotios I.F. Girtovitis, Vasilis Papagiannis, Ioannis Klonizakis, Athanasios Papadopoulos, Dimitris Bougiouklis, Afroditi A.K. Boutou, Pantelis P.E.M. Makris
Journal: Blood (2004)
Mutational Burden in Acute Myeloid Leukemia Is Largely Age Dependent
Authors: Aaron C. Shaver, Adam C. Seegmiller, Stephen A. Strickland, Robert D. Daber, Sanjay R. Mohan, Paul Brent Ferrell, Cindy Vnencak-Jones, David R. Head, Annette S. Kim, Mary M. Zutter, Michael R. Savona
Journal: Blood (2015)
Report on the International Co-Operative Study of the Effects of L-Selectin Gene Polymorphisms on the Development of Complications in Sickle Cell Disease.
Authors: Iheanyi Okpala, Cynthia C. Ugochukwu, Panagiotis Pantelidis, Baba Inusa, Obike Ibegbulam, Onyinye Onyekwere
Journal: Blood (2005)
Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts.
Authors: Mark P. Chao, Ash A Alizadeh, Chad Z. Tang, June Helen Myklebust, Bindu Varghese, Max Jan, Ronald Levy, Irving L. Weissman, Ravindra Majeti
Journal: Blood (2009)
New Aspects for Future Stratifications In Paediatric AML: Outcome According to Cytogenetics of 386 Patients Enrolled In Study AML-BFM 2004
Authors: Christine von Neuhoff, Annette Sander, Jutta Bradtke, Silja Roettgers, Andrea Teigler-Schlegel, Martin Zimmermann, Johanna Ohlendorf, Nils von Neuhoff, Ursula Creutzig, Dirk Reinhardt
Journal: Blood (2010)
Tracking Effector T Cell Dynamics and Immune Inhibitory Receptors in Patients with Acute Myeloid Leukemia (AML)
Authors: Hanna A. Knaus, Raúl Montiel-Esparza, Joshua F. Zeidner, Amanda Blackford, Christopher G. Kanakry, Ante Vulic, Mark J. Levis, Judith E. Karp, Leo Luznik, Ivana Gojo
Journal: Blood (2015)
RhG-CSF Mobilized and Apheresis-Collected Endothelial Progenitor Cells for Therapeutic Vasculogenesis.
Authors: Martin Korbling, James M. Reuben, Hui Gao, Bang-Ning Lee, Sergio A. Giralt, Issa F. Khouri, Rima M. Saliba, Richard E. Champlin, Zeev Estrov
Journal: Blood (2005)
Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study
Authors: David J Kuter, James B Bussel, Adrian Newland, Joost TM de Wolf, Troy Guthrie, Jeffrey Wasser, Lara Gehl, Kun Nie, Dietmar Berger
Journal: Blood (2008)
Minimal Residual Disease Assessed by WT1 Expression and NPM1 Mutations Specific RQ-PCR Assays Identifies Patients with Distinct Outcomes in the ALFA 0701 Trial and Is Decreased by Treatment with Gemtuzumab Ozogamicin
Authors: Juliette Lambert, Jerome Lambert, Olivier Nibourel, Cécile Pautas, Sandrine Hayette, Jean-Michel Cayuela, Christine Terre, Philippe Rousselot, Herve Dombret, Claude Preudhomme, Sylvie Castaigne, Aline Renneville
Journal: Blood (2012)
4-Log Ex-Vivo T-Lymphocyte Depleted Myeloablative HLA-Matched Sibling Transplants; a Platform for Adoptive Immunotherapy
Authors: Minoo Battiwalla, Zachariah A. McIver, Janice Haggerty, Eleftheria K. Koklanaris, Kamna Chawla, Jeanine Superata, Richard Childs, Roger Kurlander, David Stroncek, Hanh Khuu, Deborah Citrin, Marianna Sabatino, Susan Leitman, A. John Barrett
Journal: Blood (2010)
Still too little transparency among guideline writers and others
Authors: Jacqui Wise
Journal: BMJ (2017)

A series of studies published in JAMA Internal Medicine have concluded that there needs to be much greater transparency about conflicts of interest among clinicians, patient advocacy organizations, and professional groups.

One study found that the level of commercial conflicts of interest among guideline committees remains a problem.1 It found that neither the 2013 American College of Cardiology and American Heart Association cholesterol guideline nor a 2014 hepatitis C guideline from the American Association for the Study of Liver Diseases fully met the standards set by the Institute of Medicine on conflicts of interest. Standards requiring no conflict …
Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.
Authors: David J Kuter, Mathias J Rummel, Ralph Vincent Boccia, B. Gail Macik, Ingrid Pabinger, Dominik L.D. Selleslag, Francesco Rodeghiero, Beng H Chong, H. Müller-Beiβenhirtz, Lara Gehl, Xuena Wang, Dietmar Berger
Journal: Blood (2009)
SURG-28NEUROSURGICAL INTRAOPERATIVE SPECTROSCOPY: TOWARDS REAL-TIME CNS TUMOUR BIOPSIES
Authors: Babar Vaqas, Michael Short, Julia Balog, Haishan Zeng, Zoltan Takats, Kevin O'Neill
Journal: Neuro-Oncology (2015)

Immediate, real-time accurate tissue characterisation is a crucial unmet need during surgery for the maximal resection of CNS tumours whilst causing minimum damage to surrounding functioning brain tissue. We describe the first ever use of mass spectrometry and Raman spectroscopy to immediately characterize brain tumours during surgery with accuracy rivaling that of traditional histopathological techniques. A prospective observational study was designed consisting of 40 patients undergoing Neurosurgical resection of a range of WHO grade I-IV brain tumours and metastases. A Neuronavigational platform was devised combining advanced spectrometry technologies together with intraoperative imaging to allow accurate 3D spectral acquisition during surgery taking into account brain shift. The resulting data from 40 cases consists of over 1,500 brain spectra acquired during surgery with high spatial localization. Analysis shows unique spectra for each type of tumour with sensitivity and specificity comparable to the current gold standard of histopathological analysis. The spatial heterogeneity of tumour spectra sheds important light into underlying genomic and metabolomic profiles of the tumours studied including IDH-1 mutation and MGMT status. We have demonstrated that the use of molecular data with high spatial resolution obtained through mass spectral and Raman spectral analysis shows that real-time biopsies are obtainable and represent an invaluable resource in the decision making process during surgery. This also represents an opportunity to fast track vital post surgical therapies currently offered to high grade brain tumours and investigate novel aspects of in-vivo tumour biology through a new modality with the possibility of novel biomarker discovery. This sets the stage for a formal clinical trial looking into the benefits of spectral guided resection in terms of safer and more complete resection, rapid progress to further treatment and improved overall survival.
Interspinous process devices(IPD) alone versus decompression surgery for lumbar spinal stenosis(LSS): A systematic review and meta-analysis of randomized controlled trials
Authors: Xing-wen Zhao, Jian-xiong Ma, Xin-long Ma, Fei Li, Wei-wei He, Xuan Jiang, Yin Wang, Biao Han, Bin Lu
Journal: International Journal of Surgery (2017)